Removing Time from the Equation

X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our proprietary peptoid. The peptoid inhibits lethal ice crystals, allowing long-term sub-zero storage of biological materials while maintaining unparalleled functionality and viability. 

How it Began

When she was 8 years old, Xiaoxi’s beloved grandfather passed away. If he had received a donor liver, he would have had more time to spend with loved ones. 

Xiaoxi has since dedicated her life to finding a solution that increases organ availability. In 2014 she obtained her doctorate in medicinal chemistry from SUNY-Buffalo. Soon after, she established X-Therma to bring her vision of eradicating organ waitlists to life.

X-Therma History

2015

Xiaoxi Wei, CEO began her research work for X-Therma at Lawrence Berkeley National Laboratory. She received her first grant awarded to X-Therma. Provisional patent filed.

2016

Only 1 Year later X-Therma had 2 additional grants in implementation and a Team of 4. First successful proof of concept for novel preservation of cell lines.

2017

X-Therma now has 5 grants running simultaneously and filed additional provisional patents.

2018

X-Therma Partnered with Johns Hopkins University and Dr. Gerald Brandacher on several grants. X-Therma awarded first patent claim set!

2019

Successful in vivo mouse heart transplant with Johns Hopkins University.

2020

X-Therma survived the Covid-19 pandemic and was able to continue with successful ex vivo organ transplantations.

2021

X-Therma closed an oversubscribed $13M Series A financing led by LOREA AG. The European office was opened.

2022

The FDA designated X-Therma's proprietary organ preservation solution, XT-ViVo®, and TimeSeal® Organ Transport Device, Breakthrough Device status.

News